

Roles of community and sexual contacts as drivers of clade I mpox outbreaks

Hiroaki Murayama^{1†}, Toshiaki R. Asakura^{2,3,4†}, Borame L. Dickens⁵, Jen Han Foo⁵, Shihui Jin⁵, Patrick K. Mukadi^{6,7,8}, Keisuke Ejima⁹, Sung-mok Jung¹⁰, Akihiro Nishi^{11,12}, Kiesha Prem⁵, Akira Endo^{2,3,4,5*}

1. School of Medicine, International University of Health and Welfare, Narita, Japan
2. Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
3. Centre of Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK
4. School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan
5. Saw Swee Hock School of Public Health, National University of Singapore, Singapore
6. Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
7. Department of Clinical Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan
8. Department of Epidemiology and Global Health, Institut de Recherche Biomédicale, Kinshasa, Democratic Republic of Congo
9. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
10. Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11. Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, CA, USA
12. California Center for Population Research, University of California, Los Angeles, CA, USA

* Correspondence to: aendo@nus.edu.sg

† These authors contributed equally.

Abstract

Initial investigation into the emerging mpox outbreak of novel clade Ib in eastern Democratic Republic of the Congo has identified signs of sustained human-to-human transmission and epidemiological links to sexual contacts involving female sex workers (FSWs), which have not been observed in previous clade Ia outbreaks. Using mathematical models incorporating age-dependent contact patterns, we quantified the role of frequent sexual interactions as opposed to community contacts in the clade Ib dynamics and found that this additional mode of transmission could explain its increased outbreak potential compared with clade Ia. As with the globally-circulating clade Iib transmitted predominantly among men who have sex with men, our findings reinforce the importance of protecting key population groups, specifically FSWs for clade Ib, in controlling ongoing mpox outbreaks.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Main text

Since September 2023, a sustained local transmission of a novel subclade of monkeypox virus (MPXV), classified as clade Ib, has been observed in the Democratic Republic of the Congo (DRC) along with its spread to multiple other countries (1). In response to the escalating situation, the World Health Organization (WHO) declared a public health emergency of international concern (PHEIC) on 14 August 2024 (2). Clade Ib was first identified from a cluster of cases in the Kamituga health zone of the South Kivu province, eastern DRC, where an initial investigation found epidemiological links to sexual contacts and a significant proportion of female sex workers (FSWs) among reported cases (3). Genetic analyses have indicated a distinct profile from clade Ia circulating in other parts of DRC, characterised by the accumulation of apolipoprotein B mRNA editing enzyme catalytic subunit 3 (APOBEC3)-associated mutations (3). Those mutations suggest sustained human-to-human transmission and were also observed in the globally-circulating MPXV clade Iib, which primarily affected men who have sex with men (MSM) (4, 5). As of September 2024, clade Ib has shown steady growth within many health zones in the North and South Kivu provinces and introductions to other provinces of DRC (6). Additionally, international spread to neighbouring countries (Burundi, Uganda, Rwanda and Kenya) and beyond the African continent (Sweden, Thailand and India) has been confirmed, of which Burundi has reported the largest number of cases (853 as of September 2024 (1)).

MPXV clade Ia has been circulating in DRC and other Central African countries for over 50 years (7) via zoonotic transmission followed by self-limiting chains of human-to-human transmission via close contact, mostly within households (8). Since the cessation of the smallpox vaccination programme in 1980, which had provided cross-protection against mpox (9–14), DRC has seen a consistent rise in suspected mpox cases (15, 16) with the highest recorded case count of 14,626 in 2023 (3). Despite this increase, zoonotic spillover remained the primary driver of outbreaks (17, 18), and there has been no evidence of large outbreaks solely sustained by human-to-human transmission before the emergence of clade Ib in 2023. In contrast, the clade Ib outbreak in the South Kivu province has shown a clear exponential growth trend suggesting human-to-human contact as the primary mode of transmission (19, 20). The rapid rise of clade Ib cases with a potential increase in the contribution of human-to-human transmission relative to clade Ia is of growing global concern, especially given that the outbreak is not restricted to specific at-risk populations but is affecting broader groups including children (21).

The extensive clade Ib case profiles including both children and adults along with documented occupational risks among FSWs may reflect its mixed transmission routes through regular contacts in the community and through sexual contacts. Sexual contact as a novel route of transmission has also been documented in the ongoing global mpox outbreak caused by clade Iib since 2022 and was suggested to have contributed to the rapid spread among MSM (22, 23); meanwhile, sustained transmission of clade Iib through community or heterosexual contact routes has not been observed and cases were mostly restricted to the MSM group (5). If clade Ib, transmissible through heterosexual contact, continues to grow into another international mpox outbreak following clade Iib, the potentially more emphasised role of community contacts in its transmission than clade Iib may enable it to affect a larger susceptible population and pose challenges for control. Although the involvement of sexual contacts among FSWs and their clients has been well documented in the initial spread of clade Ib in the Kamituga health zone in South Kivu (21), little is currently understood on the relative contribution of community and sexual contacts to the subsequent clade Ib dynamics in broader settings not limited to Kamituga, and how they may explain the

distinct epidemiological features of clade Ib compared to clade Ia. With the gradual expansion of clade Ib within DRC and beyond borders, analytical efforts to identify its plausible transmission mechanisms and priority groups for prevention should leverage the best available evidence, if limited, to inform and support effective control policies.

In this study, we hypothesised that the entry to a key population group for sexual contacts alone may be sufficient to explain the rapid growth of the clade Ib outbreak. We developed a mathematical model for MPXV transmission dynamics incorporating both community contact route and sexual contact route involving FSWs. We first demonstrated that our model with only a community contact route can replicate the age profiles of the current and historical clade Ia outbreak datasets. We then expanded the model to include a sexual contact route to quantify the contribution of each route to the overall clade Ib transmission dynamics.

Characterising community contact transmission pattern in historical and current clade Ia outbreaks

The age-dependent contact matrix, whose entries represent the average number of contacts (typically defined as either conversational¹ or physical contacts) an individual of a specific age group has with other age groups per unit time, is a common tool for modelling transmission dynamics of directly-transmitted infections across multiple age groups. Assuming that the risk of transmission is proportional to the frequency of relevant types of contacts one experiences with infectious individuals, the contact matrix is associated with the so-called next generation matrix, a matrix that is multiplied by a vector of the number of cases by age groups in one generation to produce a vector for the next generation (24). During the exponential phase of an outbreak, the age distribution of cases would quickly converge to the dominant eigenvector of the next generation matrix and the dominant eigenvalue would define the effective reproduction number (24). We modelled the next generation matrix by combining a contact matrix informed by empirical contact survey data from Zimbabwe (25) and age-dependent susceptibility that we assumed to reflect potentially higher susceptibility among children aged 0–4 years (26) and lower susceptibility among smallpox-immunised birth cohorts (9–14).

This simple model, validated by hold-out data (Figure S1), well described the age distribution of both the historical clade Ia cases in the Tshuapa province, DRC and the recent cases in six provinces of DRC where clade Ia has been endemic, with a 10-year shift in the age of smallpox-immunised cohorts from 35 and above to 45 and above (Figures 1A and B). Our model employed four contact matrices with different contact definitions; since all four models were overall similar in goodness-of-fit, we used model averaging (27) to pool the model outputs (Table 1). The estimated susceptibility among children aged 0–4 (model averaging estimate: 1.8 [95% confidence interval: 1.2–2.4]) and smallpox-immunised cohort (0.25 [0.15–0.36]) relative to other age groups was consistent with literature, e.g. the ratio of 1.3–1.6 between the historical secondary attack risk estimates for clade Ia among age 0–4 and 5–14 (26) and the estimated effectiveness of past smallpox vaccination against clade IIb of around 70–75% (14, 28).

¹ Contact involving a minimum threshold of words exchanged during a two-way conversation without any physical contact




Figure 1. Observed and modelled age distributions of mpox cases. (A) Clade Ia cases with suspected human-to-human exposure from Tshuapa province, DRC, 2011–2015. Those aged 35 and older were assumed to be smallpox-immunised, reflecting the vaccine cessation in 1980. (B) Cases from clade Ia-endemic

provinces in DRC, January–August 2024. Those aged 45 and older were assumed to be immunised. (C)–(F) Clade Ib cases from multiple settings in DRC and in Burundi, January–August 2024. Those aged 45 and older were assumed to be fully immunised in DRC and 70% immunised in Burundi. Half-transparent lines represent the model fit without assuming transmission over sexual contact.

Table 1. Relative contribution of sexual contacts to the transmissibility of clade Ib in DRC and Burundi

Model	Contact type	Model weights*	Estimated relative susceptibility**		Estimated fraction of R_{eff} attributable to sexual transmission			
			Children aged 0–4	Immunised cohort	North and South Kivu	Kamituga health zone	Other health zones, South Kivu	Burundi
1	All contacts***	0.22	2.2 (1.8–2.5)	0.26 (0.17–0.35)	39%	59%	13%	5%
2	Physical contacts only	0.38	1.9 (1.6–2.2)	0.28 (0.18–0.38)	40%	60%	13%	6%
3	All contacts at home	0.21	1.5 (1.3–1.8)	0.22 (0.13–0.30)	42%	62%	12%	5%
4	Physical contacts at home	0.17	1.3 (1.1–1.6)	0.23 (0.15–0.32)	42%	62%	13%	4%
Model average	—	—	1.8 (1.2–2.4)	0.25 (0.15–0.36)	41%	61%	13%	5%

* May not add up to 1 due to rounding

** Referenced to pre-immunisation cohort aged 5 or older

*** Physical + conversational contacts. Physical contacts are defined as any skin-to-skin contact and conversational contacts are defined as in-person contacts with a two-way exchange of at least three words

Modelling sexual contact transmission for clade Ib outbreaks

Assuming that the community contact transmission patterns relevant to clade Ia would also apply to clade Ib transmission, we modelled a sexual contact transmission route among heterosexual individuals with high sexual activity (who we assume primarily represent FSWs and clients) on top of the community contact matrix to represent transmission dynamics of clade Ib outbreaks. We considered a simple proportionate mixing between age groups, where sexual partners are chosen randomly among those in the high-activity group of the opposite sex. We parameterised the age-dependent prevalence of male and female high-activity individuals (aged 15–19, 20–29, 30–39 and 40–49) and their mean neighbour degrees (29) over the infectious period of mpox to construct the age-, sex- and transmission-route (community vs. sexual contact)-dependent next generation matrix. We fitted our model to the age-sex distribution of clade Ib cases in multiple geographical settings: the North and South Kivu provinces (referred to as the Kivus hereafter), the Kamituga health zone, other health zones of South Kivu and Burundi. We assumed the relative susceptibility to be identical to what we estimated from clade Ia datasets, except that the susceptibility for the smallpox-immunised cohorts in Burundi reflected a lower historical coverage (70%) than in DRC (97%) (30).

Our model reproduced the observed age-sex distribution of clade Ib cases generally well, including age groups not assumed to be involved in high-activity sexual contact (Figure 1C–F). This supports the hypothesis that the transmission dynamics of clade Ib could be explained by a combination of community contact transmission patterns similar to clade Ia and an additional sexual contact transmission among the high-activity group. The estimated

role of transmission over sexual contact varied between geographical settings, potentially reflecting different sexual behaviours among high-activity individuals. The relative contribution of sexual contact to the effective reproduction number was higher in the Kivus (41%), which is most likely attributable to the dynamics in the Kamituga health zone (61%) (Table 1). In the other health zones of South Kivu (15%) and Burundi (4%), sexual contact was suggested to play a smaller (although non-negligible) role. A recent study on the Kamituga outbreak associated clade Ib spread in the region with a high number of bars serving as places for commercial sex services in the context of the local gold mining industry (31). Frequent engagement in commercial sex associated with mining work (32) in Kamituga and potentially other nearby mining areas (31) may account for the distinct epidemiological characteristics of clade Ib in the Kivus. These differences in the relative roles between community and sexual contacts could shape contrasting age-dependent transmission patterns between regions. Compared with clade Ia in the endemic provinces, clade Ib in the Kivus was estimated to be more frequently transmitted between sexually-active age groups (Figure 2A, left vs middle). Whilst such excess among the sexually-active age groups was less pronounced in Burundi, its lower vaccine coverage suggests more involvement of those aged 50 and older in community contact transmission (Figure 2A, right).

Linking transmission patterns and outbreak potential of clade I

Our models allowed us to project the time-evolving effective reproduction numbers (R_y) of MPXV clade Ia and Ib (Figure 2B). The projection suggested a 12% increase in R_y of clade Ia over the last decade in DRC, reflecting the ageing of the smallpox-immunised cohorts. Assuming an R_y of 0.82 for clade Ia in DRC, 2015 (17), this increase translates into an R_y of 0.91 in 2024, which aligns with our estimates from the pre-Ib mpox incidence data in DRC (Figure S2). As R_y gradually approaches 1, the expected final size of an outbreak initiated by a single zoonotic infection, given as $1/(1-R_y)$ (33), would have increased from 5.6 in 2015 to 11.1 in 2024, which may also explain the recent rise in clade Ia cases in the endemic areas in DRC (34).

If the same community contact transmission patterns estimated for clade Ia also apply to clade Ib, the overall R_y in the Kivus combining both community and sexual contact routes would be around 1.5 in our projection. This is similar to our estimate of the initial reproduction number from suspected clade Ib cases in South Kivu (Figure S2). The increase in R_y attributable to sexual contact, resulting in an overshoot of the epidemic threshold of one, could explain the stable exponential growth of clade Ib cases observed in the Kivus. In Burundi, our model projected that R_y for clade Ia would be 4% higher than DRC in 2024 reflecting lower smallpox vaccination coverage. With an additional sexual contact transmission route, R_y for clade Ib in Burundi may reach the epidemic threshold (with a point estimate of 1.02). Among the neighbouring countries to DRC reporting clade Ib cases, Burundi has the lowest historical smallpox vaccine coverage and is the country to report the most rapid spread as of September 2024. The slightly larger susceptible pocket bringing R_y towards the epidemic threshold in our model may be one of the factors that rendered Burundi the first country after DRC to observe a major spread of clade Ib.




Figure 2. Transmission dynamics of MPXV clade I outbreaks. (A) Age-specific transmission patterns for clade Ib in endemic provinces of DRC, North and South Kivu, and Burundi. Colours represent daily transmission rates between infector-infectee pairs in given age groups according to the estimated next generation matrices. (B) Projected effective reproduction number (R_e) for clades Ia and Ib in DRC (blue lines) and Burundi (red lines), 2010–2030. The estimated reproduction number of 0.82 from clade Ia case data between 2013–2017 in Tshuapa province, DRC (17) was used as a reference value for 2015 (the midpoint of the study period). The empirical estimates of the effective reproduction number from the DRC incidence data in the pre-clade Ib period in 2023 (pre-Ib) and from the South Kivu incidence data (SK) in 2024, as proxy data for clade Ia and Ib, respectively, are displayed as dots for comparison. Paired dots (jittered horizontally for visual aid) denote different serial interval distributions used, which were estimated elsewhere from two separate sets of infector-infectee pairs (distribution 1: mean 17.5 days; distribution 2: mean 11.4 days) (48). (C) Estimated

impact of different combinations of FSW-focused and mass vaccination strategies on the effective reproduction number in the Kivus.

Focused/mass vaccination strategies

Using the Kivus as a case study, we compared the possible impact of FSW-focused and mass vaccination strategies (Figure 2C). Given the age eligibility for vaccines (18 years and above for JYNNEOS (35)) and the previously smallpox-immunised cohort, we considered adults aged 20–39 as the primary group for mass vaccination; our results also suggested that this group is more likely to contribute to onward transmission in the Kivus (Figure 2A). Under the current global vaccine shortages, prioritising FSWs, typically accounting for < 1% of the total population (36), may allow for efficient use of available supply. In the Kivus, where sexual contact was estimated to play a substantial role in the overall dynamics, achieving a high vaccine uptake among FSWs would reduce the doses for general adults required for control (Figure 2C). Realistically, both strategies may be pursued in tandem, considering uncertainty and a possible shift in the relative role of sexual and community contact transmission as well as challenges in approaching FSWs under social barriers and stigma. Regardless of the vaccine target population, clear and supportive communication and de-stigmatisation are essential (37).

Conclusions

This study quantified the role of community and sexual contacts in MPXV clade I outbreaks. The results suggest that the past and current clade Ia outbreaks are primarily driven by community contacts, whereas clade Ib is additionally transmitted through contacts among individuals with high sexual activity such as FSWs and clients. This additional transmission route may be responsible for the increased effective reproduction number of clade Ib in the Kivus compared with clade Ia in other endemic regions. The estimated relative contribution of sexual contact was particularly pronounced in the Kamituga health zone and less so outside, suggesting that the current epidemiology of clade Ib in the Kivus may be largely attributable to sexual contact patterns specific to Kamituga and that generalisability to other settings should be discussed in conjunction with the local sociobehavioural contexts. Our results also suggest that, with the ageing of smallpox-immunised cohorts over decades, the reproduction number of MPXV clade I has already been approaching the epidemic threshold even without additional involvement of sexual contacts. In this regard, a small increment in transmission pathways, including but not limited to sexual contact, may sustain a clade I outbreak, particularly in countries with lower historical vaccine coverage.

The current MPXV clade Ib outbreak has exhibited a distinct epidemiological pattern from clade Ia outbreaks, characterised as a rapid spread involving a novel mode of human-to-human transmission through sexual contacts. A similar sudden emergence of sustained human-to-human transmission was the nature of the global clade IIb outbreak in 2022 onward, which was predominantly (if not exclusively) transmitted through sexual contacts among MSM (4). Our previous modelling work offered a plausible explanation for this transition that clade IIb established itself in a densely-connected portion of the MSM sexual network, allowing for the rapid spread that was not sustained elsewhere (22)—likewise, the emergence of clade Ib may be another example of MPXV's entry to a key population group where it can sustain itself. Whilst extensive transmission among FSWs and their clients was not specifically reported in the clade IIb global outbreak, sexual transmission of clade II involving FSWs had already been reported from 2017 (38) and the potential risk has been discussed since the initial phase of the global outbreak (39, 40). It remains unclear whether only clade Ib is able to be readily transmitted within FSW-related networks or it was just the

first to have an opportunity among the clades with a similar potential. Nevertheless, investigation and control efforts for mpox continue to require a tailored and inclusive approach, with a particular focus on the most vulnerable groups including children, MSM, FSWs and other key populations (41, 42).

Limitations & sensitivity analyses

This study holds several limitations. First, we assumed that contact survey data sufficiently represent community contacts relevant to MPXV transmission. Some forms of transmission, including fomite or nosocomial routes, may not be fully captured by the existing contact data from population samples. Contact matrices also represent the mean contact rates between age groups and neglect possible heterogeneity beyond this. We however believe our eigenvector approach with hold-out validation (Figures S1C and S1E) helped to ensure robustness. We used the empirical contact data from a different country (Zimbabwe) as a proxy since neither empirical contact data from DRC nor Burundi was available. Nevertheless, the model using Zimbabwe contact data outperformed the model using a synthetic contact matrix for DRC (Table S2 and Figure S1) and our findings remain overall consistent between these models (Figure S4).

Second, our model of the sexual contact route for clade Ib was simplistic due to limited sexual behaviour data, e.g. proportionate mixing with age-invariant contact rates. However, the estimated relative contributions of community and sexual contact routes, the primary interest of this study, would be relatively robust to these assumptions as long as our model can capture the excess in mixing patterns attributable to sexual contacts. We assumed sexual contacts outside of the high-activity groups were captured by contact survey data and had limited contribution to the difference in dynamics between clades Ia and Ib. Despite our sensitivity analyses, additional data on local sexual behaviours including the detailed distribution of sexual engagement rates in FSWs and clients would further inform the analysis. We also limited our analysis to heterosexual contacts and did not consider MSM networks. The reported clade Ib case profile as of the time of analysis does not suggest significant transmission within the MSM group (43), and our additional analysis suggests that infection- or vaccine-derived immunity in this group may lower the risk of sustained clade Ib transmission in populations previously affected by the global clade I Ib outbreak (Figure S6). However, this does not exclude the future possibility of clade Ib outbreaks among MSM, e.g. in countries without a previous clade I Ib circulation or after herd immunity is lost (44).

Finally, case data used for the analysis may have been subject to uncertainty and biases due to challenges accompanying medical attendance, testing or reporting in an outbreak that also coincided with civil conflict and disaster (45, 46). Most importantly, the potential underreporting of cases among FSWs facing criminalisation and stigma (47) may have resulted in an underestimation of the relative contribution of sexual contacts to the clade Ib dynamics.

Data and code availability

All data used in this study are publicly available. All the analysis was conducted in Julia v.1.9.3 and R v.4.3.1. Source codes are available on a GitHub repository: https://github.com/akira-endo/mpoxclade1_eigen.

Acknowledgement

H.M., T.R.A., S-m.J. and A.E. are supported by the Japan Science and Technology Agency (JST) (JPMJPR22R3, to A.E.) and Japan Agency for Medical Research and Development

(JP223fa627004). H.M. and A.E. are supported by the Japan Society for the Promotion of Science (JSPS) (JP22K17329, to A.E.). T.R.A. is also supported by the Rotary Foundation (GG2350294), the Nagasaki University World-leading Innovative & Smart Education (WISE) Program of the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the JSPS KAKENHI Grant-in-Aid for JSPS Fellows (JP24KJ1827). S-m.J. is supported by the Centers for Disease Control and Prevention Safety and Healthcare Epidemiology Prevention Research Development programme (200-2016-91781). A.E. is also supported by National University of Singapore Start-Up Grant. A.N. and A.E. are supported by the National Institutes of Health (K01AI166347, to A.N.), the National Science Foundation (NSF #2230125, to A.N.). A.N. is also supported by JST (JPMJPR21R8). S.J., G.H. and B.L.D. are supported by the Ministry of Education Reimagine Research Grant and PREPARE, Ministry of Health.

Competing interests

None declared.

Author contribution

Conceptualisation: A.E. Methodology: H.M., T.R.A., K.P. and A.E. Investigation: H.M., T.R.A. and A.E. Visualisation: H.M., T.R.A. and A.E. Data curation: T.R.A., S.J., K.P. and A.E. Funding acquisition: A.E. and A.N. Writing – original draft: H.M., T.R.A. and A.E. Writing – review and editing: B.L.D., J.H.F., S.J., P.K.M., K.E., S-m.J., A.N. and K.P.

References

1. World Health Organization, “Multi-country outbreak of mpox, External situation report #39 - 6 October 2024” (2024); <https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report--39---6-october-2024>.
2. World Health Organization, “Multi-country outbreak of mpox, External situation report#36- 14 September 2024” (2024); <https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report-36--14-september-2024>.
3. E. H. Vakaniaki, C. Kacita, E. Kinganda-Lusamaki, Á. O’Toole, T. Wawina-Bokalanga, D. Mukadi-Bamuleka, A. Amuri-Aziza, N. Malyamungu-Bubala, F. Mweshi-Kumbana, L. Mutimbwa-Mambo, F. Belesi-Siangoli, Y. Mujula, E. Parker, P.-C. Muswamba-Kayembe, S. S. Nundu, R. S. Lushima, J.-C. Makangara-Cigolo, N. Mulopo-Mukanya, E. Pukuta-Simbu, P. Akil-Bandali, H. Kavunga, O. Abdramane, I. Brosius, E. Bangwen, K. Vercauteren, N. A. Sam-Agudu, E. J. Mills, O. Tshiani-Mbaya, N. A. Hoff, A. W. Rimoin, L. E. Hensley, J. Kindrachuk, C. Baxter, T. de Oliveira, A. Ayouba, M. Peeters, E. Delaporte, S. Ahuka-Mundeke, E. L. Mohr, N. J. Sullivan, J.-J. Muyembe-Tamfum, J. B. Nachege, A. Rambaut, L. Liesenborghs, P. Mbala-Kingebeni, Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. *Nat. Med.*, 1–5 (2024).
4. World Health Organization, “Multi-country outbreak of monkeypox, External situation report #1 - 6 July 2022” (2022); <https://www.who.int/publications/m/item/multi-country-outbreak-of-monkeypox--external-situation-report--1---6-july-2022>.
5. World Health Organization, “Joint ECDC-WHO Regional Office for Europe Mpox Surveillance Bulletin: 09 October 2023” (2023); <https://www.who.int/andorra/publications/m/item/joint-ecdc-who-regional-office-for-europe-mpox-surveillance-bulletin--09-october-2023>.
6. T. Wawina-Bokalanga, P. Akil-Bandali, E. Kinganda-Lusamaki, E. Lokilo, D. Jansen, A. Amuri-Aziza, J.-C. Makangara-Cigolo, E. Pukuta-Simbu, R. Ola-Mpumbe, M.

- Muyembe, C. Kacita, P. Paku-Tshambu, P. H. Dantas, O. Tshiani-Mbaya, G. Luakanda, A. Nkuba-Ndaye, M. Matondo, E. H. Vakaniaki, S. Tessema, N. Ndembi, Á. O'Toole, T. D. Block, C. Ngandu, N. A. Hoff, N. Low, L. Subissi, S. Merritt, J.-J. Muyembe-Tamfum, L. Liesenborghs, M. Peeters, E. Delaporte, J. Kindrachuk, A. W. Rimoin, S. Ahuka-Mundeye, A. Rambaut, D. Mwamba, K. Vercauteren, P. Mbala-Kingebeni, Co-circulation of monkeypox virus subclades Ia and Ib in Kinshasa Province, Democratic Republic of the Congo, July to August 2024. *Eurosurveillance* **29**, 2400592 (2024).
7. O. Mitjà, D. Ogoina, B. K. Titanji, C. Galvan, J.-J. Muyembe, M. Marks, C. M. Orkin, Monkeypox. *The Lancet* **401**, 60–74 (2023).
 8. L. D. Nolen, L. Osadebe, J. Katomba, J. Likofata, D. Mukadi, B. Monroe, J. Doty, L. Kalemba, J. Malekani, J. Kabamba, P. L. Bomponda, J. I. Lokota, M. P. Balilo, T. Likafi, R. S. Lushima, J.-J. M. Tamfum, E. W. Okitolonda, A. M. McCollum, M. G. Reynolds, Introduction of Monkeypox into a Community and Household: Risk Factors and Zoonotic Reservoirs in the Democratic Republic of the Congo. doi: 10.4269/ajtmh.15-0168 (2015).
 9. E. Hammarlund, M. W. Lewis, S. V. Carter, I. Amanna, S. G. Hansen, L. I. Strelow, S. W. Wong, P. Yoshihara, J. M. Hanifin, M. K. Slifka, Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. *Nat. Med.* **11**, 1005–1011 (2005).
 10. K. L. Karem, M. Reynolds, C. Hughes, Z. Braden, P. Nigam, S. Crotty, J. Glidewell, R. Ahmed, R. Amara, I. K. Damon, Monkeypox-Induced Immunity and Failure of Childhood Smallpox Vaccination To Provide Complete Protection. *Clin. Vaccine Immunol.* **14**, 1318–1327 (2007).
 11. A. W. Rimoin, P. M. Mulembakani, S. C. Johnston, J. O. Lloyd Smith, N. K. Kisalu, T. L. Kinkela, S. Blumberg, H. A. Thomassen, B. L. Pike, J. N. Fair, N. D. Wolfe, R. L. Shongo, B. S. Graham, P. Formenty, E. Okitolonda, L. E. Hensley, H. Meyer, L. L. Wright, J.-J. Muyembe, Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. *Proc. Natl. Acad. Sci.* **107**, 16262–16267 (2010).
 12. M. M. Christodoulidou, N. A. Mabbott, Efficacy of smallpox vaccines against Mpox infections in humans. *Immunother. Adv.* **3**, Itad020 (2023).
 13. E. Li, X. Guo, D. Hong, Q. Gong, W. Xie, T. Li, J. Wang, X. Chuai, S. Chiu, Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus. *Signal Transduct. Target. Ther.* **8**, 1–7 (2023).
 14. S. Colombe, S. Funke, A. Koch, M. Haverkate, S. Monge, A.-S. Barret, A. Vaughan, S. Hahné, C. van Ewijk, H.-D. Emborg, S. von Schreeb, A. Díaz, C. Olmedo, L. Zanetti, D. Levy-Bruhl, L. A. de Sousa, J. Hagan, N. Nicolay, R. Pebody, Effectiveness of historical smallpox vaccination against mpox clade II in men in Denmark, France, the Netherlands and Spain, 2022. *Eurosurveillance* **29**, 2400139 (2024).
 15. N. A. Hoff, R. H. Doshi, B. Colwell, B. Kebela-Illunga, P. Mukadi, M. Mossoko, D. Spencer, J.-J. Muyembe-Tamfum, E. Okitolonda-Wemakoy, J. Lloyd-Smith, A. W. Rimoin, Evolution of a Disease Surveillance System: An Increase in Reporting of Human Monkeypox Disease in the Democratic Republic of the Congo, 2001-2013. *Int. J. Trop. Dis. Health*, 1–10 (2017).
 16. E. M. Bunge, B. Hoet, L. Chen, F. Lienert, H. Weidenthaler, L. R. Baer, R. Steffen, The changing epidemiology of human monkeypox—A potential threat? A systematic review. *PLoS Negl. Trop. Dis.* **16**, e0010141 (2022).
 17. K. Charniga, A. M. McCollum, C. M. Hughes, B. Monroe, J. Kabamba, R. S. Lushima, T. Likafi, B. Nguete, E. Pukuta, E. Muyamuna, J.-J. M. Tamfum, S. Karhemere, D. Kaba, Y. Nakazawa, Updating Reproduction Number Estimates for Mpox in the Democratic

- Republic of Congo Using Surveillance Data. doi: 10.4269/ajtmh.23-0215 (2024).
18. E. Kinganda-Lusamaki, A. Amuri-Aziza, N. Fernandez, J.-C. Makangara-Cigolo, C. Pratt, E. H. Vakaniaki, N. A. Hoff, G. Luakanda, P. Akil-Bandali, S. S. Nundu, N. Mulopo-Mukanya, M. Ngimba, B. Modadra-Madakpa, R. Diavita, P. Paku, E. Pukuta-Simbu, S. Merritt, Á. O'Toole, N. Low, A. Nkuba-Ndaye, H. Kavunga-Membo, R. Shongo, L. Liesenborghs, T. Wawina-Bokalanga, K. Vercauteren, D. Mukadi-Bamuleka, L. Subissi, J.-J. Muyembe, J. Kindrachuk, A. Ayouba, A. Rambaut, E. Delaporte, S. Tessema, E. D'Ortenzio, A. W. Rimoin, L. E. Hensley, P. Mbala-Kingebeni, M. Peeters, S. Ahuka-Mundeke, Clade I Mpox virus genomic diversity in the Democratic Republic of the Congo, 2018 - 2024: Predominance of Zoonotic Transmission. medRxiv [Preprint] (2024). <https://doi.org/10.1101/2024.08.13.24311951>.
 19. Government of the Democratic Republic of the Congo, World Health Organization, "Rapport de la situation épidémiologique de la variole simienne (Mpox) en RDC sitrep No 020 (17 au 23 Juin 2024) - Democratic Republic of the Congo | ReliefWeb" (2024); <https://reliefweb.int/report/democratic-republic-congo/rapport-de-la-situation-epidemiologique-de-la-variole-simienne-mpox-en-rdc-sitrep-no-020-17-au-23-juin-2024>.
 20. Government of the Democratic Republic of the Congo, World Health Organization, "Rapport de la situation épidémiologique de la variole simienne (Mpox) en RDC sitrep No 025 (29 août 2024) - Democratic Republic of the Congo | ReliefWeb" (2024); <https://reliefweb.int/report/democratic-republic-congo/rapport-de-la-situation-epidemiologique-de-la-variole-simienne-mpox-en-rdc-sitrep-no-025-29-aout-2024>.
 21. World Health Organization, "Mpox - Democratic Republic of the Congo" (Disease Outbreak News); <https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON522>.
 22. A. Endo, H. Murayama, S. Abbott, R. Ratnayake, C. A. B. Pearson, W. J. Edmunds, E. Fearon, S. Funk, Heavy-tailed sexual contact networks and monkeypox epidemiology in the global outbreak, 2022. *Science* **378**, 90–94 (2022).
 23. H. Murayama, C. A. B. Pearson, S. Abbott, F. Miura, S. Jung, E. Fearon, S. Funk, A. Endo, Accumulation of Immunity in Heavy-Tailed Sexual Contact Networks Shapes Mpox Outbreak Sizes. *J. Infect. Dis.* **229**, 59–63 (2024).
 24. O. Diekmann, J. A. P. Heesterbeek, M. G. Roberts, The construction of next-generation matrices for compartmental epidemic models. *J. R. Soc. Interface*, doi: 10.1098/rsif.2009.0386 (2010).
 25. A. Melegaro, E. D. Fava, P. Poletti, S. Merler, C. Nyamukapa, J. Williams, S. Gregson, P. Manfredi, Social Contact Structures and Time Use Patterns in the Manicaland Province of Zimbabwe. *PLOS ONE* **12**, e0170459 (2017).
 26. Z. Ježek, B. Grab, M. V. Szczeniowski, K. M. Paluku, M. Mutombo, Human monkeypox: secondary attack rates. *Bull. World Health Organ.* **66**, 465–470 (1988).
 27. S. T. Buckland, K. P. Burnham, N. H. Augustin, Model Selection: An Integral Part of Inference. *Biometrics* **53**, 603–618 (1997).
 28. B. K. Titanji, A. Eick-Cost, E. S. Partan, L. Epstein, N. Wells, S. L. Stahlman, P. Devineni, B. Munyoki, S. Pyarajan, A. Balajee, J. Smith, C. W. Woods, M. Holodniy, V. J. Davey, R. A. Bonomo, Y. Young-Xu, V. C. Marconi, Effectiveness of Smallpox Vaccination to Prevent Mpox in Military Personnel. *N. Engl. J. Med.* **389**, 1147–1148 (2023).
 29. M. Catanzaro, M. Boguñá, R. Pastor-Satorras, Generation of uncorrelated random scale-free networks. *Phys. Rev. E* **71**, 027103 (2005).
 30. J. C. Taube, E. C. Rest, J. O. Lloyd-Smith, S. Bansal, The global landscape of smallpox vaccination history and implications for current and future orthopoxvirus susceptibility: a modelling study. *Lancet Infect. Dis.* **23**, 454–462 (2023).

31. L. M. Masirika, J. C. UDAHemuka, L. Schuele, D. F. Nieuwenhuijse, P. Ndishimye, M. Boter, J. B. Mbiribindi, C. Kacita, T. Lang, C. Gortázar, J. P. Musabyimana, S. Otani, F. M. Aarestrup, F. B. Siangoli, B. B. O. Munnink, M. Koopmans, the G. M. Consortium, Mapping and sequencing of cases from an ongoing outbreak of Clade Ib monkeypox virus in South Kivu, Eastern Democratic Republic of the Congo between September 2023 to June 2024. medRxiv [Preprint] (2024). <https://doi.org/10.1101/2024.09.18.24313835>.
32. Sex workers find themselves at the center of Congo’s mpox outbreak | AP News. <https://apnews.com/article/mpox-outbreak-sex-workers-miners-kamituga-congo-5f6f3c7e9f0abd1917f8daf41678ea2b>.
33. G. De Serres, N. J. Gay, C. P. Farrington, Epidemiology of Transmissible Diseases after Elimination. *Am. J. Epidemiol.* **151**, 1039–1048 (2000).
34. E. M. Beer, V. B. Rao, A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. *PLoS Negl. Trop. Dis.* **13**, e0007791 (2019).
35. CDC, ACIP Recommendations, *Advisory Committee on Immunization Practices (ACIP)* (2024). <https://www.cdc.gov/acip/vaccine-recommendations/index.html>.
36. UNAIDS, “Democratic Republic of the Congo;” <https://www.unaids.org/en/regionscountries/countries/democraticrepublicofthecongo>.
37. Y. A. Adebisi, S. M. Ezema, O. Bolarinwa, A. E. Bassey, I. O. Ogunkola, Sex Workers and the Mpox Response in Africa. *J. Infect. Dis.*, jiae435 (2024).
38. D. Ogoina, A brief history of monkeypox in Nigeria (2022). <https://www.idsociety.org/science-speaks-blog/2022/a-brief-history-of-monkeypox-in-nigeria/>.
39. D. Ogoina, H. I. James, Mpox among Linked Heterosexual Casual Partners in Bayelsa, Nigeria. *N. Engl. J. Med.* **388**, 2101–2104 (2023).
40. S. A. Strathdee, A.-L. Crago, K. Shannon, Harm reduction and rights-based approaches to reduce monkeypox transmission among sex workers. *Lancet Infect. Dis.* **23**, e43–e46 (2023).
41. D. Blackburn, Epidemiologic and Clinical Features of Mpox in Transgender and Gender-Diverse Adults — United States, May–November 2022. *MMWR Morb. Mortal. Wkly. Rep.* **71** (2022).
42. E. Pembí, S. Omoleke, H. Paul, T. Augustine, L. E. Cuevas, Monkeypox outbreak in a correctional center in North Eastern Nigeria. *J. Infect.* **85**, 702–769 (2022).
43. P. D. Katoto, W. Muttamba, E. Bahizire, E. B. Malembaka, H. K. Bosa, D. M. Kazadi, G. Lubambo, F. B. Siangoli, B. Bakamutumaho, M. Wayengera, D. J. M. Landu, D. Mukadi-Bamuleka, P. Mbala, M. Loeb, B. Kirenga, J.-J. Muyembe-Tamfum, Shifting transmission patterns of human mpox in South Kivu, DR Congo. *Lancet Infect. Dis.* **24**, e354–e355 (2024).
44. A. Hazra, J. Zucker, E. Bell, J. Flores, L. Gordon, O. Mitjà, C. Suñer, A. Lemaigen, S. Jamard, S. Nozza, A. V. Nori, E. Pérez-Barragán, J. C. Rodríguez-Aldama, J. L. Blanco, C. Delaugerre, D. Turner, I. Fuertes, V. Leiro, S. L. Walmsley, C. M. Orkin, C. Creticos, P. Gibbons, Z. Maakaroun-Vermesse, C. Faussat, L. Handala, J. Zeggagh, A. Alemany, C. Galvan, A. Castagna, A. R. Raccagni, R. A. Cruz-Flores, P. F. Pardal, L. Marchetta, Mpox in people with past infection or a complete vaccination course: a global case series. *Lancet Infect. Dis.* **24**, 57–64 (2024).
45. Conflict in DR Congo: What’s happening & how to help - Democratic Republic of the Congo | ReliefWeb (2024). <https://reliefweb.int/report/democratic-republic-congo/conflict-dr-congo-whats-happening-how-help>.
46. “UNICEF Burundi Humanitarian Situation Report No. 1 (Level 3 Mpox): 25 July to 15 September 2024 - Burundi | ReliefWeb” (2024);

- <https://reliefweb.int/report/burundi/unicef-burundi-humanitarian-situation-report-no-1-level-3-mpox-25-july-15-september-2024>.
47. Exploitation, Sexual and Gender-Based Violence Increases in DRC - Democratic Republic of the Congo | ReliefWeb (2024). <https://reliefweb.int/report/democratic-republic-congo/exploitation-sexual-and-gender-based-violence-increases-drc>.
 48. V. Marziano, G. Guzzetta, I. Longini, S. Merler, Epidemiologic Quantities for Monkeypox Virus Clade I from Historical Data with Implications for Current Outbreaks, Democratic Republic of the Congo - Volume 30, Number 10—October 2024 - Emerging Infectious Diseases journal - CDC. doi: 10.3201/eid3010.240665.
 49. E. R. Whitehouse, J. Bonwitt, C. M. Hughes, R. S. Lushima, T. Likafi, B. Nguete, J. Kabamba, B. Monroe, J. B. Doty, Y. Nakazawa, I. Damon, J. Malekani, W. Davidson, K. Wilkins, Y. Li, K. W. Radford, D. S. Schmid, E. Pukuta, E. Muyamuna, S. Karhemere, J.-J. M. Tamfum, E. W. Okitolonda, A. M. McCollum, M. G. Reynolds, Clinical and Epidemiological Findings from Enhanced Monkeypox Surveillance in Tshuapa Province, Democratic Republic of the Congo During 2011–2015. *J. Infect. Dis.* **223**, 1870–1878 (2021).
 50. Mpx research and innovation - aligning research response with outbreak goals. <https://www.who.int/news-room/events/detail/2024/08/29/default-calendar/mpox-research-and-innovation---aligning-research-response-with-outbreak-goals>.
 51. World Health Organization, 2022-24 Mpx (Monkeypox) Outbreak: Global Trends. https://worldhealthorg.shinyapps.io/mpx_global/.
 52. S. Funk, L. Willem, H. Gruson, M. B.-N. Dunbar, C. A. B. Pearson, S. Clifford, C. Jarvis, A. Robert, N. Hens, P. Coletti, socialmixr: Social Mixing Matrices for Infectious Disease Modelling, version 0.3.2 (2024); <https://cran.r-project.org/web/packages/socialmixr/index.html>.
 53. K. Prem, K. van Zandvoort, P. Klepac, R. M. Eggo, N. G. Davies, C. for the M. M. of I. D. C.-19 W. Group, A. R. Cook, M. Jit, Projecting contact matrices in 177 geographical regions: An update and comparison with empirical data for the COVID-19 era. *PLOS Comput. Biol.* **17**, e1009098 (2021).
 54. R. M. Anderson, G. F. Medley, R. M. May, A. M. JOHNSON, A Preliminary Study of the Transmission Dynamics of the Human Immunodeficiency Virus (HIV), the Causative Agent of AIDS. *Math. Med. Biol. J. IMA* **3**, 229–263 (1986).
 55. M. G. M. Gomes, M. U. Ferreira, R. M. Corder, J. G. King, C. Souto-Maior, C. Penha-Gonçalves, G. Gonçalves, M. Chikina, W. Pegden, R. Aguas, Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold. *J. Theor. Biol.* **540**, 111063 (2022).
 56. Sebastian Meyer, R: Aggregate a Contact Matrix, version 0.13.3; <https://search.r-project.org/CRAN/refmans/hhh4contacts/html/aggregateC.html>.
 57. UNSD — Demographic and Social Statistics, “Demographic Yearbook – 2020” (2020); https://unstats.un.org/unsd/demographic-social/products/dyb/dyb_2020/.
 58. J. N. Inungu, B. F. N. Kandala, A. M. Atungale, Prevalence of HIV and Syphilis and Related Risk Behaviors Among Female Sex Workers in the Democratic Republic of the Congo. *Eur. J. Environ. Public Health* **6**, em0114 (2022).
 59. C. Semá Baltazar, N. Mehta, A. Jaga, M. Boothe, D. Chitsondzo Langa, P. Simbine, T. A. Kellogg, Who Are the Men Who Pay for Sex in Mozambique? Results from the National HIV/AIDS Indicator Survey 2015. *Arch. Sex. Behav.* **50**, 2057–2065 (2021).
 60. Y. Wolff Sagy, R. Zucker, A. Hammerman, H. Markovits, N. G. Arieih, W. Abu Ahmad, E. Battat, N. Ramot, G. Carmeli, A. Mark-Amir, G. Wagner-Kolasko, H. Duskin-Bitan, S. Yaron, A. Peretz, R. Arbel, G. Lavie, D. Netzer, Real-world effectiveness of a single dose of mpox vaccine in males. *Nat. Med.* **29**, 748–752 (2023).

61. K. P. Burnham, D. R. Anderson, Multimodel Inference: Understanding AIC and BIC in Model Selection. *Sociol. Methods Res.* **33**, 261–304 (2004).
62. NATSAL – The National Survey of Sexual Attitudes and Lifestyles. <https://www.natsal.ac.uk/>.
63. H. Murayama, A. Nishi, A. Endo, Different time scales used for sexual partner surveys pose a challenge in modelling dynamics of sexually transmitted infections. medRxiv [Preprint] (2023). <https://doi.org/10.1101/2023.12.25.23300526>.
64. S. P. C. Brand, M. Cavallaro, F. Cumming, C. Turner, I. Florence, P. Blomquist, J. Hilton, L. M. Guzman-Rincon, T. House, D. J. Nokes, M. J. Keeling, The role of vaccination and public awareness in forecasts of Mpox incidence in the United Kingdom. *Nat. Commun.* **14**, 4100 (2023).
65. X.-S. Zhang, S. Mandal, H. Mohammed, C. Turner, I. Florence, J. Walker, S. Niyomsri, G. Amirthalingam, M. Ramsay, A. Charlett, P. Vickerman, Transmission dynamics and effect of control measures on the 2022 outbreak of mpox among gay, bisexual, and other men who have sex with men in England: a mathematical modelling study. *Lancet Infect. Dis.* **24**, 65–74 (2024).
66. N. L. Bragazzi, S. A. Iyaniwura, Q. Han, W. A. Woldegerima, J. D. Kong, Quantifying the basic reproduction number and underestimated fraction of Mpox cases worldwide at the onset of the outbreak. *J. R. Soc. Interface* **21**, 20230637 (2024).
67. F. Branda, M. Pierini, S. Mazzoli, Monkeypox: Early estimation of basic reproduction number R_0 in Europe. *J. Med. Virol.* **95**, e28270 (2023).

Supplementary text: Materials and methods

Data sources

We used the numbers of confirmed mpox cases by age and sex in both historical and current outbreaks from public sources (49, 50). Details of the datasets are available in Table S1. Weekly incidence data for DRC and South Kivu were also collected from public reports (19, 20, 51). Empirical contact survey data in Zimbabwe (25) and population age distributions in DRC and Burundi were retrieved via {socialmixr} R package (52). We also used synthetic contact matrix data published by Prem et al. (53).

Table S1. MPXV clade I outbreak datasets.

Label	Location	Year	Clade	Exposure type	N	Reference
1	Tshuapa province, DRC	2011-2015	Ia	Zoonotic*	308	(49)
2	Tshuapa province, DRC	2011-2015	Ia	Human-to-human**	279	(49)
3	Six endemic provinces***, DRC	2024 [†]	Ia	Not classified	482	(50)
4	North and South Kivu provinces, DRC ^{††}	2024 [†]	Ib	Not classified	1,377	(50)
5	Kamituga health zone, South Kivu ^{††}	2024 [†]	Ib	Not classified	725	(50)
6	Other health zones, South Kivu ^{††}	2024 [†]	Ib	Not classified	510	(50)
7	Burundi	2024 [†]	Ib	Not classified	250	(50)

* Defined by reporting only exposure to an animal within 3 weeks before onset

** Defined by reporting only exposure to a human with a rash illness only within 3 weeks before onset

*** Equateur, South and North Ubangi, Sankuru, Thsopo and Tshuapa

[†] As of 18 August 2024

^{††} North and South Kivu provinces data also contains cases in Kamituga and other health zones of South Kivu.

Model structure

We assumed that the observed number of mpox cases by age or by age and sex follows a multinomial distribution with probabilities proportional to the elements of the dominant eigenvector of the contact matrix.

$$i \sim \text{Multinom} \left(\sum i, v(K) \right), \quad (1)$$

where $v(K)$ is the normalised dominant eigenvector of the next generation matrix K . We constructed the next generation matrix as a product of transmissibility β , age-dependent relative susceptibility σ_a and a contact matrix C . We used age-disaggregated case data and contact matrices for the analysis of clade Ia; i.e. $C = \{c_{ab}\}$, where c_{ab} represents the mean number of community contacts (conversational and/or physical, depending on the type of contact matrix used) an individual from age group b has per unit time with those from age group a . We used multiple contact matrices potentially relevant to mpox transmission (Table S2). For each contact matrix, β was adjusted so that the dominant eigenvector of the next generation matrix estimated for the historical Tshuapa dataset is equal to the previously estimated reproduction number of 0.82 (17).

For the analysis of clade Ib, we used age-and-sex-disaggregated case data and expanded the contact matrix to account for heterosexual transmission dynamics in addition to community contacts. We stratified male and female populations into high and low sexual activity groups. Following the approach in Endo et al. (22), we further stratified cases in the high-activity groups by their route of exposure (community- vs sexually-associated exposures) and allowed sexually-acquired cases to have higher risks of onward sexual transmission because of a substantial variance in sexual behaviour (54, 55). We assumed that this variance effect is negligible among low-activity groups (such that stratification by exposure route can be disregarded) and that their sexual contacts are reflected in the existing contact matrices, whose definition of contacts includes sexual contacts.

Let subscripts H and L denote high- and low-activity groups and M/m and F/f represent male and female cases with sexual (upper-case) and community exposures (lower-case), respectively. Vectors i_X represent the age-stratified number of mpox infections in category X . The generation-wise reproduction process of i_X 's is then described in a block matrix format (each block is an 8-by-8 matrix accounting for age group stratification) as:

$$\begin{bmatrix} i_{M_H}^{t+1} \\ i_{m_H}^{t+1} \\ i_{M_L}^{t+1} \\ i_{F_H}^{t+1} \\ i_{f_H}^{t+1} \\ i_{f_L}^{t+1} \end{bmatrix} = B_\sigma \begin{bmatrix} O & O & O & S_{MF} & \Sigma_{MF} & O \\ PC_{MM} & PC_{MM} & PC_{MM} & PC_{MF} & PC_{MF} & PC_{MF} \\ (I-P)C_{MM} & (I-P)C_{MM} & (I-P)C_{MM} & (I-P)C_{MF} & (I-P)C_{MF} & (I-P)C_{MF} \\ S_{FM} & \Sigma_{FM} & O & O & O & O \\ QC_{FM} & QC_{FM} & QC_{FM} & QC_{FF} & QC_{FF} & QC_{FF} \\ (I-Q)C_{FM} & (I-Q)C_{FM} & (I-Q)C_{FM} & (I-Q)C_{FF} & (I-Q)C_{FF} & (I-Q)C_{FF} \end{bmatrix} \begin{bmatrix} i_{M_H}^t \\ i_{m_H}^t \\ i_{M_L}^t \\ i_{F_H}^t \\ i_{f_H}^t \\ i_{f_L}^t \end{bmatrix}, \quad (2)$$

where O and I are zero and unit matrices, respectively. S_{MF} and S_{FM} are block contact matrices representing heterosexual transmission from sexually-acquired high-activity individuals. Similarly, Σ_{MF} and Σ_{FM} represent heterosexual transmission from community-acquired high activity individuals. Note that we expect S_X to be larger than Σ_X because

sexually-acquired cases are more likely to have more sexual partners than the population average. $P=(p_a)$ and $Q=(q_a)$ are diagonal matrices representing the age-dependent prevalence of high-activity individuals for males and females, respectively. C_X is a sex-specific contact matrix and is assumed to be half of the sex-aggregated contact matrix hereafter for simplicity. We define B_σ as a diagonal block matrix whose diagonal blocks are an 8-by-8 diagonal matrix of the age-specific susceptibility σ_a multiplied by transmissibility β . Noting that for $t \geq 1$, $i_{m_H} = P(i_{m_H} + i_{m_L})$ and $i_{f_H} = Q(i_{f_H} + i_{f_L})$, the above relationship can be simplified into

$$\begin{bmatrix} i_{M_H}^{t+1} \\ i_m^{t+1} \\ i_{F_H}^{t+1} \\ i_f^{t+1} \end{bmatrix} = B_\sigma \begin{bmatrix} O & O & S_{MF} & \Sigma_{MF}Q \\ C_{MM} & C_{MM} & C_{MF} & C_{MF} \\ S_{FM} & \Sigma_{FM}P & O & O \\ C_{FM} & C_{FM} & C_{FF} & C_{FF} \end{bmatrix} \begin{bmatrix} i_{M_H}^t \\ i_m^t \\ i_{F_H}^t \\ i_f^t \end{bmatrix}, \quad (3)$$

where $i_m = i_{m_H} + i_{m_L}$ and $i_f = i_{f_H} + i_{f_L}$.

We assumed proportionate mixing to model S_{MF} , S_{FM} , Σ_{MF} and Σ_{FM} ; further details on parameterisation are described in the next section.

We constructed a multinomial likelihood for the observed number of male and female cases by age group:

$$i \sim \text{Multinom} \left(\sum i, [i_{M_H} + i_m; i_{F_H} + i_f] \right), \quad (4)$$

where $[i_{M_H} + i_m; i_{F_H} + i_f]$ is a vector obtained by sex-wise aggregation of the normalised dominant eigenvector of the next generation matrix in Equation 3.

Table S2. Community contact matrices used for analysis.

Label	Contact type	Contact setting	Data type	Country	Reference	Validation loss*
1	All	All	Empirical	Zimbabwe	(25)	44.33
2	Physical only	All	Empirical	Zimbabwe	(25)	45.56
3	All	Home	Empirical	Zimbabwe	(25)	41.00
4	Physical only	Home	Empirical	Zimbabwe	(25)	41.94
5	All	All	Synthetic	DRC	(53)	77.36
6	All	Home	Synthetic	DRC	(53)	60.05

* Negative log likelihood times two for the validation dataset (Dataset 3) not used in training

Model fitting

Our model fitting process was two-fold. We first fitted and validated the model of community contact transmission using the age distributions of cases from the historical and current clade Ia outbreaks in DRC. We then used this model to estimate age-dependent susceptibility parameters σ_a for the community contact matrix. We then constructed an expanded contact

matrix including sexual contacts and calibrated it to the age-sex distributions of cases from clade Ib outbreaks in DRC and Burundi in order to estimate additional parameters that describe transmission dynamics of clade Ib through community and sexual contact routes.

(i) Analysis of clade Ia outbreaks

As in the previous section, we defined the next generation matrix $K = \{k_{ab}\} = \beta \sigma_a c_{ab}$. The contact matrix c_{ab} was constructed from existing datasets (Table S2). Based on data availability, we used 6 age groups (0-4, 5-10, 10-19, 20-29, 30-39 and 40+) for the 2011–2015 Tshuapa data and 8 age groups (0-4, 5-10, 10-14, 15-19, 20-29, 30-39, 40-49 and 50+) for the 2024 DRC endemic provinces data. When the age groups in the case data were coarser than the contact matrix, the elements were merged accordingly (56). Transmissibility β is a nuisance scaling parameter and was not estimated. We assumed that children aged 0-4 years have a potentially higher susceptibility to infection and that adults born before the cessation of the smallpox vaccine in 1980 (11) may have lower susceptibility. To account for this, we parameterised σ_a as

$$\sigma_a = \begin{cases} \sigma_0 & (\text{aged } 0 - 4) \\ 1 - \varepsilon & (\text{smallpox immunised}) \\ 1 & (\text{otherwise}) \end{cases} . \quad (5)$$

The susceptibility for the age group that contains both vaccinated and unvaccinated cohorts was assumed to be the average of those cohorts. Specifically, we assigned a susceptibility of $1 - \varepsilon/2$ to the 30-39 age group in the historical Tshuapa dataset and the 40-49 age group in the 2024 outbreak datasets, assuming 35 and 45 years are the cutoff for the vaccination cohorts, respectively. We assumed that the immunised cohorts in DRC are almost fully vaccinated (30). We estimated σ_a by maximising the multinomial likelihood in Equation 1 and obtained 95% confidence intervals (CIs) using the Fisher information matrix.

The exploratory model development was done using the historical Tshuapa dataset. The resulting model, described above, was then validated using the 2024 DRC endemic provinces dataset. We estimated two parameters σ_0 and ε from the historical Tshuapa dataset alone and compared the model outputs (with a 10-year shift in the age of the vaccinated cohort) with the age distribution from the (hold-out) 2024 DRC endemic provinces dataset (Figure S1). The model outputs showed good overall concordance with the validation data. We obtained final parameter estimates from the joint estimation using both datasets for the subsequent analyses.

(ii) Analysis of clade Ib outbreaks

We parameterised the block components representing sexual contacts among high-activity individuals S_{MF} and S_{FM} in Equation 3 as follows. We assumed age groups of 15-19, 20-29, 30-39 and 40-49 years potentially contain high-activity populations, i.e. $p_a = q_a = 0$ outside those age groups. We assumed a simple proportionate mixing assumption (i.e. no age assortativity) where each high-activity individual with sexually-acquired infection makes sexual contacts at a specified rate over the infectious period of MPXV (w_F and w_M for female and male, respectively), which are randomly assigned to other high-activity individuals of the opposite sex irrespective of age. Note that w_F and w_M are defined to have the same scale as the community contact matrix in relation to onward transmission, i.e. one unit of w_F or w_M represents the amount of sexual contact that contributes to transmission equivalent to one daily community contact. The entries of S_{MF} and S_{FM} are then modelled as:

$$\begin{aligned}(S_{MF})_{ab} &= w_F \frac{n_a p_a}{\sum_a n_a p_a}, \\ (S_{FM})_{ab} &= w_M \frac{m_a q_a}{\sum_a m_a q_a},\end{aligned}\tag{6}$$

where n_a and m_a are the relative population size for males and females by age group (we assumed even sex distribution (57), i.e. $\sum_a n_a = \sum_a m_a = 1/2$). We assumed proportionality between S_X and Σ_X :

$$\Sigma_{MF} = \alpha_F S_{MF}, \Sigma_{FM} = \alpha_M S_{FM}.\tag{7}$$

We assumed female sex workers (FSWs) represent the behaviour of the majority of high-activity female individuals and used an FSW survey data from DRC (58) to estimate α_F , the ratio between the average number of sexual partners among community- and sexually-acquired female high-activity cases. Noting that this ratio corresponds to the ratio between the mean degree and the mean neighbour degree, we can characterise its reciprocal α_F^{-1} by the mean μ and standard deviation (SD) σ of the sexual contact degree distribution $p(x)$:

$$\alpha_F^{-1} = \frac{\int_0^\infty x^2 p(x) dx}{(\int_0^\infty x p(x) dx)^2} = 1 + \frac{\sigma^2}{\mu^2}.\tag{8}$$

We used the reported mean and SD for the weekly number of clients (mean: 17.61; SD: 12.0) and non-paying partners (mean: 5.51; SD: 22.0) per FSW (58) to derive $\alpha_F^{-1} = 2.17$ as the ratio for the total sexual partners per high-activity female (where μ and σ reflect the sum of independent random variables). The ratio for high-activity males can then be specified by the relationship required by the reciprocity of contacts: $\alpha_F w_F \sum_a m_a q_a = \alpha_M w_M \sum_a n_a p_a$. We also set boundary conditions for the total number of high-activity individuals, i.e. $\sum_a n_a p_a$ and $\sum_a m_a q_a$. Namely, we assumed that high-activity males account for 10% of the male population among the sexually-active age groups and high-activity females 1% of the total female population, based on engagement data in commercial sex in Africa (proportion of reporting paid sex in the last 12 months among males aged 15-59 in Mozambique (59) and the estimated number of FSWs per capita in DRC (36)).

Assuming the community transmission patterns are similar between clades Ia and Ib, we used the same σ_a estimated for clade Ia across regions in DRC. For Burundi with a lower historical smallpox vaccine coverage (30), we assumed a 70% coverage in the smallpox-immunised cohort and adjusted σ_a accordingly. The rest of the parameters, p_a , q_a , w_F , w_M were estimated by maximising the multinomial likelihood.

Model averaging and outputs

We used model averaging over candidate models using different contact matrix data (Table S2) with weights of the combined likelihood for datasets 2, 3 and 4 in Table S1. We did not include the likelihood for subprovincial datasets (datasets 5 and 6) and Burundi (dataset 7) in the weights due to overlapping cases and potentially different data collection and contexts, respectively. Models 5 and 6 using synthetic contact matrices had substantially worse likelihood than other models resulting in effectively zero weights and thus were not included in the main analysis.

(i) Frequency of transmission between age groups

We estimated the relative frequency of infector-infectee age pairs at equilibrium using the next generation matrix and the normalised dominant eigenvector:

$$M = B_{\sigma} \begin{bmatrix} O & O & S_{MF} & \Sigma_{MF}Q \\ C_{MM} & C_{MM} & C_{MF} & C_{MF} \\ S_{FM} & \Sigma_{FM}P & O & O \\ C_{FM} & C_{FM} & C_{FF} & C_{FF} \end{bmatrix} \text{diag} \left[\begin{bmatrix} i_{MH}^t \\ i_m^t \\ i_{FH}^t \\ i_f^t \end{bmatrix} \right]. \quad (9)$$

We then aggregated the block elements of M to obtain a sex- and transmission-route aggregated frequency matrix.

(ii) Projection of time evolution of the reproduction numbers

We projected the effective reproduction number of mpox in DRC and Burundi by shifting the age of the smallpox-immunised cohort. Referring to the previous estimate (17), we assumed the effective reproduction number of clade Ia in the Tshuapa province was 0.82 in 2015 (midpoint of the estimation period 2013–2017). We then simulated the effective reproduction number for clade Ia between 2010 and 2030 as the dominant eigenvector of the next generation matrix where the relative susceptibility of age groups including the immunised cohort was adjusted according to the estimated protection ε and the proportion of immunised cohort (approximating uniformly distributed age) within the age groups. The vaccine uptake in the immunised cohort in DRC and Burundi was assumed to be 100% and 70%, respectively (30). For clade Ib, we projected the effective reproduction number for 2024 onward assuming the shared parameters relevant to the community contact transmission between clades Ia and Ib.

(iii) The effective reproduction numbers under focused and mass vaccination scenarios

We modelled the change in the effective reproduction number of clade Ib under a combination of FSW-focused and mass vaccination scenarios. We used a vaccine effectiveness estimate of 86% (60), which we assumed to protect against infection but not against onward transmission in the case of breakthrough infections. FSW-focused vaccination was assumed to be offered to female high-activity individuals of age 20–39. For mass vaccination, all individuals aged 20–39 years, regardless of sexual activity levels, were included. The baseline effective reproduction numbers without vaccines were matched to the values projected in (ii) for each population setting.

Supplementary text: Additional results

Model validation results

A null model that assumed constant age-dependent susceptibility (i.e. the age distribution of cases should follow the eigenvector of the original contact matrices) did not produce a good fit to the historical Tshuapa dataset particularly in age groups 0–4 and 30+ (Figures S1A and B). A model with two parameters σ_0 and ε (susceptibility for age 0–4 and vaccine protection) trained on the Tshuapa dataset showed an improved fit (Figures S1C and D). The model validation using the 2024 endemic provinces dataset, which was not used in model development and training, was overall supportive of our models with a preference for the use of empirical contact matrices over synthetic contact matrices (Table S2), where a difference of 10 or more suggests strong support (61).




Figure S1. Model training and validation. (A) Null-model outputs for the historical Tshuapa dataset, 2011–15 using empirical contact matrices and (B) using synthetic contact matrices. (C) Model training outputs for the historical Tshuapa dataset, 2011–15 using empirical contact matrices and (D) using synthetic contact matrices. (E) Model validation outputs for the endemic provinces dataset, 2024, using empirical contact matrices and (F) using synthetic contact matrices.

Effective reproduction numbers for clade Ia and Ib in DRC from the recent data

We estimated the effective reproduction number (R_{eff}) for clades Ia and Ib from the recent incidence data using the renewal equation following Marziano et al. (48). The reported incidence from DRC in September 2023 onward contains both clades Ia and Ib. We therefore estimated R_{eff} for clade Ia by using only the confirmed number of cases in DRC between January to August 2023 (51). We assumed a constant incidence from zoonotic spillover events (three cases per week) based on the estimated annual spillover rate of 132 per year in DRC (17) (Figure S2B). For R_{eff} of clade Ib, we used suspected case data from South Kivu

reported in the DRC situation reports (19, 20). We assumed no zoonotic spillover in South Kivu, where mpox was not endemic before the emergence of clade Ib. We used two serial intervals, each estimated as a Weibull distribution from a separate set of infector-infectee pairs in Marziano et al. (48).

Our R_{eff} estimates for clade 1a between January to August 2023 in DRC were 0.85 (0.78–0.93) and 0.83 (0.76–0.91) using estimated serial interval distributions: distribution 1 with a mean of 17.5 days (from two household outbreaks in Sudan in 2005 and in Central African Republic in 2021-2022) and distribution 2 with a mean of 11.4 days (from a hospital-associated outbreak in the Republic of the Congo in 2003) in Marziano et al. (48), respectively (Figure S2D). Median estimates of R_{eff} for clade Ib in 2024 in South Kivu were 1.50 (1.46 - 1.55) and 1.37 (1.33 - 1.41) for each serial interval, respectively.




Figure S2. Epidemic curves and effective reproduction numbers for clades Ia and Ib in DRC. (A) Epidemic curves for suspected and confirmed cases in DRC in 2023–2024. (B) Epidemic curve of confirmed cases including assumed constant spillovers in DRC in 2023. Incidence in the pre-clade Ib period (before September 2023) was assumed to represent clade Ia. Data in the shaded period was excluded from R_{eff} estimation due to combined reporting of clades Ia and Ib. (C) Epidemic curve of suspected cases in South Kivu, 2024, assumed to represent clade Ib. (D) Estimated R_{eff} for the clade Ia and Ib using pre-clade Ib DRC and South Kivu incidence data, respectively. We used different serial interval distributions estimated from two separate sets of infector-infectee pairs for estimation, denoted by suffixes 1 and 2.

Estimated impact of FSW-focused and mass vaccination strategies in Burundi on the effective reproduction number

Following the approach of Figure 2C in the main text, we also projected the possible impact of different combinations of FSW-focused and mass vaccination strategies on effective reproduction number in Burundi. Caution is warranted given the uncertainty due to the limited sample size for Burundi including potentially underestimated contribution of sexual contact transmission.




Figure S3. Estimated vaccine impact in Burundi. Comparison of the estimated impact between focused vaccination for female sex workers (FSWs) and mass vaccination strategies on the effective reproduction numbers in Burundi.

Sensitivity analysis: synthetic contact matrix

We used synthetic contact matrices for DRC and Burundi in place of the empirical contact matrices from Zimbabwe (Figure S4). The likelihood-based model weights strongly preferred the contact matrix at home, effectively excluding the all-setting contact matrix as an alternative. The estimated relative contribution to the effective reproduction number was 48%, 66%, 22% and 14% for the Kivus, Kamituga, other health zones and Burundi, respectively. Higher estimates than those from empirical contact matrices may be because the model underestimated cases aged 20–29 than observed in the endemic provinces in 2024 (Figure S1F).




Figure S4. Modelled age distributions of mpox clade I cases using synthetic matrices. (A-D) Clade Ib cases from multiple settings in DRC and in Burundi, January–August 2024. Those aged 45 and older were assumed to be fully vaccinated in DRC and 70% vaccinated in Burundi. Half-transparent lines represent the model fit without assuming transmission over sexual contact.

Speed of convergence to eigenvector

We assessed the validity of our assumption that the observed distributions of cases are representative of the dominant eigenvector of the next generation matrix. First, we used the age distribution of cases with zoonotic exposure in the 2011–2015 Tshuapa dataset (i.e. Dataset 1 in Table S1) as the initial distribution (generation 0). We then iteratively left-multiplied this distribution with the next generation matrix based on each type of contact matrix to generate the distribution of subsequent human-to-human transmission generations. The results showed that the convergence is rapid enough for all human-exposed cases (generation 1 onward) to follow the dominant eigenvector (Figures S5A). Similarly, for our

model of a mixed mode of community and sexual contact transmission, we simulated the age-sex distribution of cases by generations starting from high-activity initial cases (all in the age group 20–29 and evenly distributed between males and females). The age-sex distribution exhibited a rapid convergence (Figure S5B).




Figure S5. Convergence of case distribution to the dominant eigenvector of the next generation matrix. (A) Simulated age distributions of cases across generations based on different contact matrices with community contact transmission only. Initial cases were assumed to follow the reported age distribution of cases with zoonotic exposure in Tshuapa, 2011–2015. (B) Simulated age and sex distributions of

cases across generations based on different contact matrices with both community and sexual contact transmission. Initial cases were assumed to be all 20–29 and evenly distributed between males and females.

Outbreak potential of clade I among MSM in a population with immunity from the previous clade IIb global outbreak

In our main analysis, we only focused on the heterosexual contact network and did not consider transmission over the men who have sex with men (MSM) sexual contact network. As MSM have been the most affected group in the clade IIb global outbreak since 2022, assessment of clade I's transmission potential in this group, particularly in the presence of immunity, is of public health interest.

To assess the outbreak potential of clade I in a population with infection-derived and/or vaccine-derived immunity from the previous clade IIb outbreak and vaccination, we used a deterministic transmission model accounting for highly heterogeneous distribution of sexual partners among MSM developed in Murayama et al. (23), which we updated using a 4-week partnership data (as opposed to the 1-year partner data used in the original study) from the British National Surveys of Sexual Attitudes and Lifestyles (62, 63). We assumed that an MSM population that previously experienced a clade IIb epidemic had reached the natural final epidemic size and established long-term herd immunity. The initial effective reproduction number of a new clade in such a population with assumed completely cross-protective immunity from the clade IIb epidemic is then given as:

$$R_{\text{eff}}^{\text{new}} = \frac{\beta_{\text{new}} \int_1^{\infty} x(x-1)S_{\text{final}}(x)dx}{\langle x \rangle}, \quad (10)$$

where β_{new} is the secondary attack risk (SAR) per sexual partnership for the new clade, $\langle x \rangle$ is the mean degree (the average number of sexual partners) and S_{final} is the number of susceptible individuals with x partners per capita (23). Note that the bracket is the expectation operator over the population. For a clade I major outbreak to occur, the initial effective reproduction number needs to meet the condition of $R_{\text{eff}}^{\text{new}} \geq 1$, which gives us the threshold for β_{new} and thus the basic reproduction number (R_0^{new}) required for the epidemic takeoff. In the presence of population-level vaccine protection, the required R_0 would be $1/(1-v)$ -fold, where v is the relative risk of infection among the vaccinated population. We assumed vaccines were randomly allocated and with an effectiveness of 86% (60). For simplicity, we neglected the impact of vaccination on the real-time dynamics of the previous clade IIb outbreak was minimal, as suggested by previous studies (64, 65). We defined the effective susceptible proportion as the ratio between the initial effective reproduction number of a new clade (Equation 10) and its basic reproduction number in a fully-susceptible population:

$$S_{\text{eff}} = \frac{R_{\text{eff}}^{\text{new}}}{R_0^{\text{new}}} = \frac{\int_1^{\infty} x(x-1)S_{\text{final}}(x)dx}{\langle x(x-1) \rangle}. \quad (11)$$

Note that $R_0^{\text{new}} = \beta_{\text{new}} \langle x(x-1) \rangle / \langle x \rangle$.

By simulating the model, we showed the effective susceptible proportion and R_0 required for clade I's epidemic takeoff as a function of R_0 of clade II in the previous outbreak (Figure S6). R_0 for clade IIb has been estimated mostly around 2 to 3 (65, 66, 67). Within this range, the effective susceptible proportion is 10%–30%, requiring an R_0^{new} of 3 to 8 to cause a major

outbreak even without any vaccination. If 50% of the population is vaccinated, the effective susceptible proportion drops to about 5%–15%, requiring an R_0^{new} of at least 6.

These results suggest that the risk of another major mpox outbreak within MSM populations may be low in countries affected by the 2022 outbreak if existing immunity confers sufficient cross-protection.




Figure S6. Outbreak potential of clade I within the MSM community with herd immunity established in the clade IIb global outbreak. The relationships between the basic reproduction number for clade IIb and (A) effective susceptible proportion represented as $R_{\text{eff}}^{\text{new}}/R_0^{\text{new}}$; (B) the clade I's basic reproduction number required to initiate a major outbreak with different vaccination uptake.